Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.JAMA Oncol. 2017; 3: 1335-1342
- Nothing but NET: a review of neuroendocrine tumors and carcinomas.Neoplasia. 2017; 19: 991-1002
- Somatostatin receptor imaging of endocrine gastrointestinal tumors.Schweiz Med Wochenschr. 1992; 122: 634-637
- Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.Cancer Res. 1994; 54: 3455-3459
- Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET/CT.AJR Am J Roentgenol. 2018; 211: 267-277
- (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2021; 22: 1752-1763
- ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues.Neuroendocrinology. 2017; 105: 295-309
- NANETS/SNMMI consensus statement on patient selection and appropriate Use of (177)Lu-DOTATATE peptide receptor radionuclide therapy.J Nucl Med. 2020; 61: 222-227
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2020; 31: 844-860
- The New World Health Organization classification for pancreatic neuroendocrine neoplasia.Endocrinol Metab Clin North Am. 2018; 47: 463-470
- The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors.Eur J Nucl Med Mol Imaging. 2017; 44: 468-475
- 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.Nucl Med Commun. 2019; 40: 1195-1203
- ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging.Neuroendocrinology. 2017; 105: 212-244
- High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.J Nucl Med. 2014; 55: 1786-1790
- 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.Clin Cancer Res. 2010; 16: 978-985
- (18)F-FDG PET is superior to who grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study.J Nucl Med. 2021; 62: 808-815
- Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?.J Nucl Med. 2014; 55: 1811-1817
- Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.J Nucl Med. 2010; 51: 704-712
- Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.Theranostics. 2017; 7: 1149-1158
- Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival.J Clin Oncol. 2008; 26
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study.Eur J Nucl Med Mol Imaging. 2011; 38: 2125-2135
- Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.Neuroendocrinology. 2013; 97: 347-354
- Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.Eur J Nucl Med Mol Imaging. 2017; 44: 490-499
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.Pancreas. 2014; 43: 518-525
- 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.Eur J Nucl Med Mol Imaging. 2014; 41: 1845-1851
- (177)Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.Eur J Nucl Med Mol Imaging. 2021; 48: 152-160
- Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.Eur J Nucl Med Mol Imaging. 2015; 42: 1238-1246
- Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors.J Clin Endocrinol Metab. 2019; 104: 1336-1344
- Efficacy of (177)Lu-dotatate induction and maintenance therapy of various types of neuroendocrine tumors: a phase II registry study.Curr Oncol. 2020; 28: 115-127
- Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable/metastatic neuroendocrine tumors.Clin Nucl Med. 2020; 45: e393-e399
- Surgical feasibility, determinants, and overall efficacy of neoadjuvant (177)Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors.J Nucl Med. 2021; 62: 1558-1563
- Safety and response after peptide receptor radionuclide therapy with (177) Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial.J Hepatobiliary Pancreat Sci. 2022; 29: 487-499
- Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.New Engl J Med. 2017; 376: 125-135
- Recommendations for management of patients with neuroendocrine liver metastases.Lancet Oncol. 2014; 15: e8-e21
- The epidemiology of metastases in neuroendocrine tumors.Int J Cancer. 2016; 139: 2679-2686
- One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.J Clin Oncol. 2008; 26: 3063-3072
- Liver-directed therapy for neuroendocrine tumor liver metastases in the era of peptide receptor radionuclide therapy.Semin Intervent Radiol. 2020; 37: 499-507
- Non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors.J Clin Med. 2019; 8
- ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site.Neuroendocrinology. 2016; 103: 172-185
- GEP-NETS update: interventional radiology: role in the treatment of liver metastases from GEP-NETs.Eur J Endocrinol. 2015; 172: R151-R166
- Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.Cardiovasc Intervent Radiol. 2013; 36: 449-459
- Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.Cancer Biother Radiopharm. 2013; 28: 534-540
- Prognostic factors for chemoembolization in liver metastasis from endocrine tumors.Hepatogastroenterology. 2004; 51: 1751-1756
- Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival.Cardiovasc Interv Radiol. 2017; 40: 69-80
- Treatment of liver metastases from midgut neuroendocrine tumours: a systematic review and meta-analysis.J Clin Med. 2019; 8
- Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study.Ann Oncol. 2018; 29: viii471
- Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy.Cardiovasc Intervent Radiol. 2020; 43: 246-253
- 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.J Nucl Med. 2012; 53: 1663-1669
- Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?.Nucl Med Commun. 2020; 41: 1242-1249
- Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.Lancet Oncol. 2020; 21: 561-570
- Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2015; 42: 176-185
- Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study.Clin Nucl Med. 2017; 42: e457-e466
- Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.Eur J Nucl Med Mol Imaging. 2021; 48: 3260-3267
- EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.Eur J Nucl Med Mol Imaging. 2008; 35: 1405-1412
- EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.Eur J Nucl Med Mol Imaging. 2022; 49: 1778-1809
- Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience.Cancer Biother Radiopharm. 2016; 31: 189-198
- Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.Eur J Nucl Med Mol Imaging. 2018; 45: 970-988
- A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity.EJNMMI Phys. 2016; 3: 21
- Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases.J Nucl Med. 2019; 60: 1406-1413
- Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.J Nucl Med. 2010; 51: 1049-1058
- Radiation-associated kidney injury.Int J Radiat Oncol Biol Phys. 2010; 76: S108-S115
- Tolerance of normal tissue to therapeutic irradiation.Int J Radiat Oncol Biol Phys. 1991; 21: 109-122
- Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.J Nucl Med. 2013; 54: 33-41
- Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy.EJNMMI Phys. 2018; 5: 1-19
- Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.Eur J Nucl Med Mol Imaging. 2017; 44: 1480-1489
- Correlation of dose with toxicity and tumour response to (90)Y- and (177)Lu-PRRT provides the basis for optimization through individualized treatment planning.Eur J Nucl Med Mol Imaging. 2018; 45: 2426-2441
- A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours.Physica Med. 2018; 56: 41-49
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
